As of 2024-12-11, the EV/EBITDA ratio of Alnylam Pharmaceuticals Inc (ALNY) is -258.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Alnylam's latest enterprise value is 32,673.04 mil USD. Alnylam's TTM EBITDA according to its financial statements is -126.61 mil USD. Dividing these 2 quantities gives us the above Alnylam EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.2x - 29.9x | 12.1x |
| Forward P/E multiples | 11.0x - 15.3x | 12.3x |
| Fair Price | (10.40) - (14.43) | (11.38) |
| Upside | -104.1% - -105.7% | -104.5% |
| Date | EV/EBITDA |
| 2024-12-04 | -257.85 |
| 2024-12-03 | -255.95 |
| 2024-12-02 | -257.14 |
| 2024-11-29 | -257.20 |
| 2024-11-27 | -257.88 |
| 2024-11-26 | -257.49 |
| 2024-11-25 | -255.07 |
| 2024-11-22 | -248.87 |
| 2024-11-21 | -250.81 |
| 2024-11-20 | -252.84 |
| 2024-11-19 | -238.05 |
| 2024-11-18 | -236.01 |
| 2024-11-15 | -239.36 |
| 2024-11-14 | -262.13 |
| 2024-11-13 | -268.95 |
| 2024-11-12 | -273.38 |
| 2024-11-11 | -284.45 |
| 2024-11-08 | -282.02 |
| 2024-11-07 | -276.71 |
| 2024-11-06 | -277.51 |
| 2024-11-05 | -269.65 |
| 2024-11-04 | -274.40 |
| 2024-11-01 | -278.43 |
| 2024-10-31 | -270.97 |
| 2024-10-30 | -286.15 |
| 2024-10-29 | -289.41 |
| 2024-10-28 | -291.67 |
| 2024-10-25 | -289.59 |
| 2024-10-24 | -298.58 |
| 2024-10-23 | -299.78 |
| 2024-10-22 | -301.42 |
| 2024-10-21 | -296.87 |
| 2024-10-18 | -300.86 |
| 2024-10-17 | -301.70 |
| 2024-10-16 | -305.57 |
| 2024-10-15 | -292.13 |
| 2024-10-14 | -288.02 |
| 2024-10-11 | -289.04 |
| 2024-10-10 | -283.23 |
| 2024-10-09 | -275.36 |
| 2024-10-08 | -275.66 |
| 2024-10-07 | -271.16 |
| 2024-10-04 | -272.40 |
| 2024-10-03 | -273.97 |
| 2024-10-02 | -276.03 |
| 2024-10-01 | -280.62 |
| 2024-09-30 | -279.57 |
| 2024-09-27 | -279.45 |
| 2024-09-26 | -279.10 |
| 2024-09-25 | -277.23 |